ADCT — Adc Therapeutics Share News
0.000.00%
Last trade - 00:00- $190.22m
- $387.28m
- $81.36m
U.S. STOCKS ON THE MOVE-Expedia, Moderna, HubSpot
U.S. STOCKS ON THE MOVE-C4 Therapeutics, Eagle Bulk, SilverBow Resources
U.S. STOCKS ON THE MOVE-Wyndham Hotels, Alphabet, Candel Therapeutics
U.S. STOCKS ON THE MOVE-Oracle, Emergent BioSolutions, Eagle Bulk Shipping
ADC Therapeutics rises on positive trial data for lymphatic cancer drug combo
Brief: ADC Therapeutics Receives NYSE Notice Of Non-Compliance With Continued Listing Standards
Brief: ADC Therapeutics - Expected Cash Runway Into Mid-2025
ADC Therapeutics SA expected to post a loss of 63 cents a share - Earnings Preview
Brief: ADC Therapeutics Announces Updates On Zynlonta® Lotis Clinical Trial Programs
ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary
ADC Therapeutics SA expected to post a loss of 46 cents a share - Earnings Preview
Brief: Overland ADCT Biopharma Announces NMPA Accepts Biologics License Application And Grants Priority Review For Zynlonta® For Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Brief: ADC Therapeutics Announces Plan To Discontinue The Phase 2 Lotis-9 Clinical Trial Of Zynlonta, Rituximab
Brief: ADC Therapeutics Announces Voluntary Pause Of Enrollment In Phase 2 Lotis-9 Clinical Trial Of Zynlonta And Rituximab
ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy (updated)
ADC Therapeutics falls on pausing enrollment for cancer therapy study
ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy
Brief: ADC Therapeutics Announces Evolution Of Board Of Directors
Brief: ADC Therapeutics Announces Updated Lotis-2 Results